RiverGlades Family Offices’s Pfizer PFE Stock Holding History

RiverGlades Family Offices’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,965	Closed	-$219K	–	78
2023 Q2	$219K	Buy	+5,965	New	+$232K	0.2%	71
2023 Q1	–	Sell	-4,750	Closed	-$243K	–	80
2022 Q4	$243K	Buy	+4,750	New	+$228K	0.22%	68
2022 Q2	$249K	Sell	4,750 -2,000	-30%	-$102K	0.23%	64
2022 Q1	$349K	Sell	6,750 -1,500	-18%	-$77.8K	0.26%	62
2021 Q4	$487K	Hold	8,250	–	–	0.35%	45
2021 Q3	$355K	Hold	8,250	–	–	0.28%	53
2021 Q2	$323K	Hold	8,250	–	–	0.25%	61
2021 Q1	$299K	Hold	8,250	–	–	0.24%	62
2020 Q4	$304K	Sell	8,250 -446	-5%	-$16.4K	0.26%	58
2020 Q3	$303K	Hold	8,696	–	–	0.29%	50
2020 Q2	$270K	Hold	8,696	–	–	0.28%	53
2020 Q1	$269K	Buy	+8,696	New	+$296K	0.29%	51
2018 Q4	–	Sell	-6,651	Closed	-$278K	–	67
2018 Q3	$278K	Sell	6,651 -1,792	-21%	-$69K	0.24%	59
2018 Q2	$291K	Sell	8,443 -4,058	-32%	-$139K	0.25%	56
2018 Q1	$421K	Buy	12,501 +5,313	+74%	+$183K	0.34%	48
2017 Q4	$247K	Buy	+7,188	New	+$245K	0.2%	64

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RiverGlades Family Offices's PFE Position: Q3 2023 in Review

RiverGlades Family Offices sold out of Pfizer (PFE) in Q3 2023, closing a stake of 5,965 shares — an estimated $219K sold.

RiverGlades Family Offices first reported a position in PFE in Q4 2017 and held it in 16 quarters. The position peaked at $487K in Q4 2021. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

RiverGlades Family Offices reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
RiverGlades Family Offices sold 5,965 Pfizer shares in Q3 2023, an estimated $219K.
RiverGlades Family Offices first reported a position in Pfizer in Q4 2017 and held it in 16 quarters.
RiverGlades Family Offices's Pfizer position peaked at $487K in Q4 2021.
2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on RiverGlades Family Offices's 13F filing for Q3 2023, filed 14 Nov 2023.